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Background and purpose   The validity of various data sources 
for the assessment of the outcome quality of medical devices was 
investigated by comparative analysis of the published data sources 
available for a sample of implants. It was the aim of the study to 
determine the performance of this implant and to identify poten-
tial bias factors inherent to the various datasets.
Methods   A comprehensive literature search was carried out 
from English-language, peer-reviewed journals and worldwide 
reports from national arthroplasty registers. Publications from 
Medline-listed journals were included. The main parameter was 
revision rate, calculated as “revisions per 100 observed com-
ponent years” to allow adjusted direct comparison of different 
datasets.
Results   Of 16 clinical studies that met the inclusion criteria, 
9 originated from the implant developer’s hospital. In the clini-
cal studies category, publications from the developer’s hospital 
suggested considerably lower revision rates than the other data-
sets. In fact, the values quoted were 5.5 times below the average 
of all other studies, and 9.51 times lower than in the Australian 
arthroplasty register. These differences are statistically signifi-
cant.
Interpretation   The cementless Taperloc stem is an implant that 
shows good performance regarding revision rates in registry data 
and in clinical studies. However, the excellent results published by 
the developer’s clinic are generally not reproducible by other sur-
geons. In terms of reference data, registry data are able to make 
an important contribution to the assessment of clinical sample-
based studies, particularly regarding evaluation of the extent to 
which published results are reproducible in daily routine.
 
The Taperloc hip stem is a commonly used arthroplasty prod-
uct that has been used worldwide for many years. This implant 
was developed in cooperation with Dr Richard H. Rothman of 
the Rothman Institute, PA, USA and is marketed by Biomet 
Orthopedics Inc. It is available as a cemented and an unce-
mented variant.
The scope of the EU Commission’s EUPHORIC (European 
Public Health Outcome Research and Indicator Collection) 
project, included an examination of the validity of sources of 
information available for outcome quality assessment of med-
ical devices. This involved comparative and comprehensive 
evaluation of various literature sources such as peer-reviewed 
journal publications, meta-analyses, and registry data. The 
present study uses survival rate as the primary parameter for 
the assessment of long-term results. 
A major consideration in the evaluation of clinical literature 
by the readers of such publications is their expectation to learn 
from the results published, and to be able to reproduce these 
results. Factors such as patient selection, the fact that most 
studies are conducted in specialized centers of excellence, or 
possible publication bias may have a considerable influence 
on the outcome. 
Since the aim of national arthroplasty registries is to cover 
all cases occurring in a particular country as completely as 
possible, bias factors due to patient selection or the influence 
of any particular hospital can largely be excluded. These data-
sets are therefore well-suited to be used as reference data for 
the evaluation of bias factors in sample-based studies. How-
ever, in the assessment of registry data from other countries 
it should be taken into account that these data reflect national 
circumstances such as the surgical techniques used in a partic-
ular country, or the country’s general healthcare system. These 
circumstances—in addition to the evaluation procedures—
may lead to misinterpretations (Labek et al. 2008).
Material and methods
A web-based literature search for the terms “Taperloc”, “hip 
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common resources such as PubMed and the Directory of 
Open Access Journals. This was followed by a manual lit-
erature search, as well as a direct request for literature from 
the manufacturer of the implant. A total of 21 publications 
were recorded and analyzed in full text (Sharkey et al. 1990, 
Hozack et al. 1994, Hearn et al. 1995, McLaughlin and Lee 
1995, 1997, 2000, 2006, Rothman et al. 1996, Rao et al. 1998, 
Lewis 2000, Keisu et al. 2001a, b, Purtill et al. 2001, Sakalkale 
et al. 2001, Mallory et al. 2002, Abboud et al. 2004, Bezwada 
et al. 2004, Parvizi et al. 2004a, b).
We used the following inclusion criteria for consideration 
in the subsequent evaluation: (1) unambiguous identification 
of the implant; (2) revision rate data either presented in the 
text or unambiguously calculable from the data contained; 
(3) English-language publications in Medline-listed, peer-
reviewed journals; and (4) a minimum of 30 patients exam-
ined to exclude experimental studies and studies with a main 
goal other than outcome, which might have an influence on 
patient selection.
16 publications fulfilled these criteria (Hozack et al. 1994, 
1996, Hearn et al. 1995, Rothman et al. 1996, McLaughlin and 
Lee 1995, 1997, 2000, 2006, Keisu et al. 2001a, b, Purtill et al. 
2001, Mallory et al. 2002, Abboud et al. 2004, Bezwada et al. 
2004, Parvizi et al. 2004a, b).
The main evaluation criterion was the indicator “revision 
rate”, a variation of which, “Revisions per 100 observed 
component years”, was used for comparative assessment. 
It was applied in accordance with the Australian National 
Arthroplasty Register’s definition (Australian National Joint 
Replacement Registry 2003).  The methodology is a standard 
procedure in epidemiology and was used, for example, for 
cohort studies in the 1950s concerning the effect of smoking 
on the incidence of lung cancer and cardiovascular diseases 
(Doll and Hill 1956).
 In principle, this method deals with calculating a correla-
tion between the incidence of a potential risk exposure (e.g. 
smoking or implantation of an artificial joint implant) and a 
consequential event (e.g. lung cancer or revision surgery). 
Since individual years of follow-up are counted, studies with 
a large number of patients and long follow-up periods have 
higher impact on the aggregated dataset than small or short-
term studies. This allows direct comparison of different stud-
ies and data sources including adjustment for number of cases 
and follow-up period.
A value of 1 revision per 100 observed component years 
corresponds to a revision rate of 5% at 5 years, or a 10% revi-
sion rate at 10 years, in conventional follow-up studies. To be 
rated as an outlier dataset, the average value had to show a 
statistically significant difference in the outcome and at least a 
difference of 300% to the benchmark in registry datasets. The 
national hip and knee registers in Sweden and Denmark pub-
lish outcome from individual departments, which show devia-
tions of up to a factor of 3 for the outlier departments (Annual 
Report of the Swedish Hip Register 2008, Annual Reports of 
the Swedish and Danish Knee Registers 2009, Danish Hip 
Register 2009). This deviations in outcome were rated as 
explicable differences in average patient service due to cumu-
lative effects of impact factors such as surgeon’s expertise, 
training activities of the departments, internal and external 
quality control activities, patient selection or the public health 
system.
The journal publications included were analyzed regard-
ing their year of publication, source of publication, follow-
up period, authors, geographic region, and number of cases. 
These data were contrasted with the results for the Taperloc 
implant available from the latest annual reports of national 
registries, which were accessed via the internet at http://www.
efort.org/education/registers.aspx. Data from the Australian 
National Joint Registry were available. Unfortunately, the reg-
istry report does not differentiate between the individual com-
ponents revised, but only represents the revision of the implant 
system. As opposed to the majority of clinical studies, isolated 
cup revisions can thus not be derived directly, so the data were 
adjusted for a worldwide average benchmark.
A worldwide comparison among national arthroplasty 
registers presenting an exact distribution of the components 
concerned showed that in about two-thirds of the cases of hip 
arthroplasty revision, the stem component was also affected. 
For further calculations, this rate was transferred to the data 
from the Australian registry (Table 1). 
For all data sources, the data were pooled in a standardized 
way. For any parameter except follow-up time, exact values 
had to be included in the study.
If no specific follow-up times but follow-up periods were 
given, a linear distribution of cases was assumed. To deter-
mine statistical significance, 95% confidence intervals and 
Poisson regression analyses were calculated using the Stata 
MP software version 10.1 (StataCorp LP, College Station TX).
Results
All 16 publications of clinical studies that were finally 
included in the detailed analysis originated from USA. 9 arti-
cles (Hozack et al. 1994, 1996, Hearn et al. 1995, Rothman 
et al. 1996, Keisu et al. 2001a, b, Purtill et al. 2001, Parvizi 
et al. 2004a, b) were published by the developer’s institution 
(Department of Orthopedic Surgery, the Rothman Institute, 
Philadelphia, PA). 4 papers (McLaughlin and Lee 1995, 1997, 
2000, 2006) originated from the Center for the Hip and Knee, 
Oshkosh, WI, and the remaining 3 publications came from 
other hospitals (Mallory et al. 2002, Abboud et al. 2004, Bez-
wada et al. 2004). 2 publications from McLaughlin and Lee 
(1995, 1997) appear to have been based on the same study, 
since they included the same number of patients, revisions, 
and follow-up period. According to the general procedures for 
metanalyses, both were included in the evaluation as indepen-
dent publications.Acta Orthopaedica 2011; 82 (2): 143–148  145
All papers were published between 1994 and 2006, with the 
highest publication frequency in 2004 (4 papers), followed by 
2001 (3 papers). 
The studies included were published in 4 internationally 
renowned journals: Journal of Bone and Joint Surgery (JBJS; 
American and British editions), Journal of Arthroplasty, and 
Clinical Orthopaedics and Related Research. One study was 
published as an AAOS congress contribution.
None of the publications included registry data. Three 
papers were multicenter studies (Abboud et al. 2004, Keisu 
et al. 2001b, McLaughlin and Lee 2006) and all others were 
monocentric. The majority of papers were based on data from 
retrospective clinical studies. Parvizi et al. (2004b) conducted 
a prospective clinical study. Mallory et al. (2002) performed 
a meta-analysis. 
The 16 publications included involved treatment of 1,929 
cases in total. However, due to the large proportion of publi-
cations from the developer’s institution, multiple mentions of 
patients in different papers cannot be excluded. The number 
of cases described in the individual studies varied between 30 
(Hozack et al. 1994) and 312 patients (Hozack et al. 1999), 
with the average number of cases in the 16 studies amounting 
to 120 (median 105).
The follow-up periods ranged from 2.2 years (Rothman et 
al. 1996) to 14.6 years (McLaughlin and Lee 2006), the aver-
age follow-up period being 8.35 years (median 8).
The majority of papers came to a positive assessment of 
the cementless Taperloc hip stem prosthesis. There were no 
clearly negative statements about the product.
Almost all studies used scores as an additional criterion to 
measure implant efficiency, pain, and patient satisfaction. The 
two scores used were the Harris hip scoring system and the 
Charnley modified Merle D’Aubigné and Postel scale for pain 
and function. 
Registry data were available from the Australian National 
Joint Replacement Registry. From 1999 to 2008, 1,638 Taper-
loc stems were reported to be used in combination with the 
Mallory head, Recap and M2a cup; these three groups did not 
show any statistically significant differences in outcome. The 
cumulative number of cases in the Australian registry accounts 
for approximately the same number of cases described in stud-
ies from elsewhere. However, the average follow-up period 
(3.2 years) was considerably lower than in clinical studies. 
An analysis of the publications according to the basic data 
revealed a striking difference in the distribution of revision 
rates published. The majority of publications from the Roth-
man Institute stated that there were no revisions or very low 
revision rates, and they showed a notable divergence from reg-
istry data and other publications (Figure) (Table 2).
To determine the significance of these differences, we calcu-
lated the revisions per 100 observed component years. In a con-
ventional meta-analysis of all clinical studies, regular impact 
factors  showed a value of 0.22 (CI: 0.16–0.31), adjusted for 
the number of cases and follow-up period. Compared to the 
Australian registry, which showed a value of 0.57 (CI: 0.40–
0.81), the probability of revisions was 2.6 times higher. This 
difference was found to be statistically significant. 
A comparative stratification of the dataset of clinical studies 
in publications from the developer’s institution and all other 
publications showed that users outside the developer’s clinic 
had a revision rate that was 5.5 times higher. Compared to 
the registry dataset, the difference amounts to 9.51 fold. These 
differences were found to be statistically significant.
In contrast, the difference between developer-independent 
publications and registry datasets corresponded to a ratio of 
1.73. Although this difference was found to be statistically 
significant, it is not clinically relevant and is within the bound-
aries explicable by regular impact factors (Table 3). 
Discussion
There are some limitations to the validity of the data that this 
study is based on, as a result of estimations which were neces-
sary to allow for the comparison of different datasets. Also, 
patient characteristics such as age and gender might differ in 
the individual datasets. Consideration of these aspects in the 
Table 1. Distribution of revision surgeries with regard to the compo-
nents revised; deviations from 100% correspond to other reasons 
such as isolated head or inlay exchanges
Country/Register  Reference  Cup Stem  All 
Denmark  Annual Report 2006  31%  32%  32%
England & Wales  4th Annual Report  24%  26%  54%
Norway  Annual Report 2008  26%  22%  39%
Sweden  Annual Report 2008  31%  16%  47%
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structured analysis was not possible because of the lack of pub-
lished information and due to the inhomogeneity of studies.
For the Australian National Joint Replacement Registry, 
dataset allocation of the reason for revision to a component 
of the implant was not possible and had to be estimated. It 
is unlikely, however, that this would have a substantial effect 
on the final conclusions when differences of 951% were 
observed. Comparative analysis of the datasets has yielded 
several observations that should lead to critical scrutiny.
Systematic analysis of the data published about the cement-
less Taperloc stem revealed a strikingly high influence of the 
developer’s clinic: 44.53% of all cases and 39.2% of observed 
component years were published by this institution. However, 
with regard to revision rate this dataset differs considerably 
in outcome from the reference data in the Australian registry 
Knee Register 2009, Danish Hip Register 2009). Since one of 
the most important reasons for the success of the Scandinavian 
registries is the reduction of individual hospitals’ variances in 
revision rates through the higher-than-average improvement 
of low-performing hospitals, one can assume that there is a 
higher variation between results in individual hospitals in the 
US. The extent to which the other hospitals that have pub-
lished follow-up studies on the Taperloc stem differ from the 
developer’s institute as regards expertise should be critically 
examined. In any case, the data available allow us to make the 
conclusion that the outcome data achieved by the developing 
hospital are not reproducible by the average user worldwide.
Thus, the high influence of the developing institution could 
have a relevant impact on the average results published about 
the product. 
Table 2. Summary and description of individual publications of clinical studies 
included in the meta-analysis
 A  B  C D E  F G  H
Hozack et al.  1994  3.8  0  94  0  357  0.00
Hearn et al.  1995  3.0  2.7  30  1  90  1.11
McLaughlin et al.  1995  9.7  4.3  114  5  1,106  0.45
Hozack et al.  1996  6.1  1  105  1  638  0.16
Rothman et al.  1996  2.2  0  104  0  229  0.00
McLaughlin et al.  1997  10.0  4.3  114  5  1,140  0.44
McLaughlin et al.  2000  10.2  2  100  2  1,020  0.20
Keisu et al.  2001  5.0  0  92  0  460  0.00
Keisu et al.  2001  8.0  0  39  0  312  0.00
Purtill et al.  2001  11.0  0.5  180  1  1,980  0.05
Mallory et al.  2002  8.7  0.3  312  1  2,727  0.04
Abboud et al.  2004  3.2  0  53  0  167  0.00
Bezwada et al.  2004  3.5  4.8  168  8  588  1.36
Parvizi et al.  2004  9.7  0  86  0  830  0.00
Parvizi et al.  2004  11.0  0.7  129  1  1,419  0.07
McLaughlin et al.  2006  14.6  5.2  209  11  3,051  0.36
A Authors 
B  Year of publication 
C Follow­ up (years) 
D Revision rate (%) 
E  No. of primary cases 
F  No. of revision cases 
G Observed component years 
H Revisions per 100 observed component years
Table 3. Comparison of revision rates between clinical studies and registry data
  A B  C  D  E  F
Developer’s studies  859  4 0.06 9.51 3.17–35.2  < 0.001
Other clinical studies  1,070 32  0.33 1.73 1.06–2.86 0.03
Registry data (adjusted)  1,638 30  0.57
A  No. of primary cases 
B  No. of revision cases 
C Revisions per 100 observed component years 
D Ratio difference to registry 
E  CI ratio 
F  p­value ratio difference to registry
and developer-independent publications. Even in 
a conventional meta-analysis of the data, the high 
influence of the developer’s institution has a statis-
tically significant effect on the overall result, which 
has also been demonstrated in the meta-analysis by 
Mallory et al. (2002).
Several points should be considered in the inter-
pretation of the data:
1. Influence of the developing hospital
Developers of implants have several particularities 
that might influence the outcome:
•	 As	a	rule,	the	hospital	concerned	can	rely	on	
a high degree of expertise and a fundamental 
understanding of the product and its handling
•	 High	personal	motivation	can	be	assumed	when	
it comes to the thorough investigation of poten-
tial outcome-relevant flaws in the entire course 
of therapy and drawing the consequences. 
•	 The	final	result	of	a	THA	implantation	depends	
on a variety of factors, such as the product, 
instrumentation, operating technique, patient 
selection, etc. Since every product is developed 
against a specific background and based on a 
specific set of experiences, the product might 
make particular allowance for the factors prevail-
ing at that particular hospital 
•	 Last	but	not	least,	there	are	the	implant	design-
er’s and the manufacturer’s own interests in the 
success of the product.
2. Differences in outcome and reproducibility of 
the results of others, i.e. the average surgeon
Drawing on the differences in revision rate among 
individual hospitals in Sweden for interpretation 
of the divergences shows that the best departments 
deviate from the national average by a factor of 2 
to 3 (Annual Report of the Swedish Hip Register 
2008, Annual Reports of the Swedish and Danish Acta Orthopaedica 2011; 82 (2): 143–148  147
As a rule, the circumstances surrounding journal publica-
tion are favorable for publishing studies from the developing 
institution:
•	 It	can	be	assumed	that	implant	developers	have	a	strong	
commitment and a high scientific interest and motivation 
regarding follow-up so that there is sufficient material for 
journal publications
•	 Developing	hospitals	are	the	first	to	have	access	to	new	
implants and are thus the first to be able to publish results.
  These publications are of innovative quality and are there-
fore attractive for journals
•	 As	a	rule,	development	teams	closely	cooperate	with	implant	
manufacturers, thus having access to resources that, among 
other things, can be used in follow-up and publications 
•	 Since	studies	are	also	used	in	the	marketing	of	the	respec-
tive implant, manufacturers and developers are much more 
interested in publication than is usually the case for projects 
based exclusively on academic motivation, or for average 
users.
The majority of journal publications report a lower prob-
ability of revision than registry data. In this respect, a funda-
mental difference in the basic data must be taken into account: 
clinical studies are based on samples, which implies that any 
transference of results involves potential confounders. For 
example, the vast majority of publications originate from spe-
cialized centers, which are not representative of the worldwide 
or national average in all aspects. As opposed to this, registry 
data contain almost all surgeries performed in a country and 
therefore comprise the entire range of treatment, thus reduc-
ing bias factors and allowing better generalization in the area 
covered by the registry. The transference of results to other 
countries naturally creates confounders due to the local back-
ground, but its influence is considerably lower than in meta-
analyses of clinical studies.
For the cementless Taperloc stem, there are no sufficient 
data currently available from national registries other than 
the Australian one. For other implants, however, such com-
parisons have shown that deviation from the average outcome 
value of the respective implant by a factor of 3 is not reached 
in any case. 
Regarding the deviations in revision rates between individ-
ual hospitals within a certain country, without specifying fac-
tors such as implant selection, surgical techniques, the profile 
of the department, or other confounders, and between coun-
tries regarding the outcome achieved with the same implant, 
deviations by a factor of 3 appear to be explicable.
Thus, publications by authors who are not directly involved 
in the process of development of an implant on average show 
results that are reproducible in the registry, even though the 
average revision rates are below those of the Australian reg-
istry. The average revision rates published by the developer’s 
institution, however, do not appear to be reproducible by other 
users. On average, they are approximately 9.5 times higher in 
the Australian register, and about 5 times higher with other 
users in the USA. The specific circumstances of a developing 
hospital therefore seem to affect the results.
3. Basic characteristics of the datasets that are being com-
pared
In any evaluation, special consideration has to be given to the 
particular features inherent to the various datasets involved. 
As mentioned before, sample-based studies are usually con-
ducted in specialized centers and subject to several influencing 
factors, such as the study design, patient selection, etc. How-
ever, the different factors influencing the results of sample-
based studies are frequently not or only insufficiently apparent 
from the publications while they may have a relevant impact 
on the study results and lead to a remarkable variance in out-
comes. This reduces the reliability of the data for conclusions, 
particularly when individual centers are overrepresented.
Registry data can be a valuable supplement for evaluation of 
the revision rates to be expected by the scientific community. 
Due to their higher degree of standardization and complete-
ness in case recording at the national level, their validity is on 
average superior to that of sample-based clinical studies. Opti-
mum reference values, however, can only be obtained within 
the coverage area of a register since the circumstances under 
which the data have been collected are always reflected in the 
results. Setting up of a registry should therefore be aspired to 
in every country.
It would generally be desirable if a large number of hospitals 
and surgeons were to undertake structured patient follow-ups 
and publish the results. This could at least reduce confounders 
due to individual circumstances in different hospitals.
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